A Case of Autoimmune Neutropenia That Responded to Rituximab

Overview

Journal J Med Cases

Specialty General Medicine

Date 2024 Nov 29

PMID 39610908

Authors

Justin Dejia Wang

Danielle Brazel

Emily Nagler

Affiliations

Soon will be listed here.

Abstract

Autoimmune neutropenia (AIN) refers to the immune-mediated destruction of neutrophils. It is a rare condition with an estimated prevalence of less than 1 case per 100,000 per year. Typical treatment involves supportive care with granulocyte colony-stimulating factor (G-CSF) and management of secondary infections with antibiotics. Other therapies targeted at the immune system such as steroids, intravenous immunoglobulin (IVIG), and rituximab have not been thoroughly evaluated, but recently rituximab has shown promising results in one case series. We present a 76-year-old man with the diagnosis of antineutrophil antibody-negative AIN and concurrent immune thrombocytopenic purpura (ITP), whose AIN was treated initially with G-CSF which had a short-lived effect, then treated with rituximab which induced a lasting remission. We then review this case in context of other cases described in the literature, given the paucity of available publications.

References

Fioredda F, Skokowa J, Tamary H, Spanoudakis M, Farruggia P, Almeida A . The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action. Hemasphere. 2023; 7(4):e872. PMC: 10065839. DOI: 10.1097/HS9.0000000000000872. View

Shastri K, Logue G . Autoimmune neutropenia. Blood. 1993; 81(8):1984-95. View

Bigot W, Viallard J, Sellam J, Dellal A, Retbi A, Gobert D . Efficacy and safety of rituximab for autoimmune neutropenia: a French case series and literature review. Rheumatology (Oxford). 2020; 59(9):2637-2640. DOI: 10.1093/rheumatology/keaa045. View

Newburger P . Autoimmune and other acquired neutropenias. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):38-42. PMC: 5380382. DOI: 10.1182/asheducation-2016.1.38. View

Capsoni F, Sarzi-Puttini P, Zanella A . Primary and secondary autoimmune neutropenia. Arthritis Res Ther. 2005; 7(5):208-14. PMC: 1257445. DOI: 10.1186/ar1803. View

Starkebaum G . Chronic neutropenia associated with autoimmune disease. Semin Hematol. 2002; 39(2):121-7. DOI: 10.1053/shem.2002.31918. View

Afzal W, Owlia M, Hasni S, Newman K . Autoimmune Neutropenia Updates: Etiology, Pathology, and Treatment. South Med J. 2017; 110(4):300-307. DOI: 10.14423/SMJ.0000000000000637. View

Boxer L, Greenberg M, Boxer G, Stossel T . Autoimmune neutropenia. N Engl J Med. 1975; 293(15):748-53. DOI: 10.1056/NEJM197510092931505. View

Mariotti J, Caberlon S, Bertinato E, Podda G, Pugliano M, Cattaneo M . Primary autoimmune neutropenia in adults: case report and review of the literature. Transfusion. 2014; 54(11):2906-10. DOI: 10.1111/trf.12711. View

10.

Akhtari M, Curtis B, Waller E . Autoimmune neutropenia in adults. Autoimmun Rev. 2009; 9(1):62-6. DOI: 10.1016/j.autrev.2009.03.006. View

11.

Mitsogianni M, Mitsimponas N, Haase S, Giagounidis A . Treatment of Combined Autoimmune Neutropenia and Immune Thrombocytopenia with Methotrexate. Acta Haematol. 2019; 143(1):89-90. DOI: 10.1159/000500872. View

12.

Bux J, Behrens G, Jaeger G, Welte K . Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood. 1998; 91(1):181-6. View

13.

Kumakura S, Kobayashi S . Autoimmune neutropenia. Intern Med. 2003; 42(2):133-4. DOI: 10.2169/internalmedicine.42.133. View

14.

Dungarwalla M, Marsh J, Tooze J, Lucas G, Ouwehand W, Pettengell R . Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology. Ann Hematol. 2006; 86(3):191-7. DOI: 10.1007/s00277-006-0202-5. View